• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations.

作者信息

Verghese Michelle, Jiang Becky, Iwai Naomi, Mar Marilyn, Sahoo Malaya K, Yamamoto Fumiko, Mfuh Kenji O, Miller Jacob, Wang Hannah, Zehnder James, Pinsky Benjamin A

机构信息

Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.

Clinical Virology Laboratory, Stanford Health Care, Stanford, California, USA.

出版信息

J Clin Microbiol. 2021 Jun 18;59(7):e0074121. doi: 10.1128/JCM.00741-21.

DOI:10.1128/JCM.00741-21
PMID:33952596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8218743/
Abstract
摘要

相似文献

1
A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations.一种具有L452R和E484Q中和抗性突变的新型冠状病毒变异株。
J Clin Microbiol. 2021 Jun 18;59(7):e0074121. doi: 10.1128/JCM.00741-21.
2
In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.体外数据表明，SARS-CoV-2 的印度德尔塔变异株 B.1.617 能够通过受体亲和力和免疫逃避来逃避中和作用。
Allergy. 2022 Jan;77(1):111-117. doi: 10.1111/all.15065. Epub 2021 Sep 14.
3
Impact of E484Q and L452R Mutations on Structure and Binding Behavior of SARS-CoV-2 B.1.617.1 Using Deep Learning AlphaFold2, Molecular Docking and Dynamics Simulation.利用深度学习 AlphaFold2、分子对接和动力学模拟研究 E484Q 和 L452R 突变对 SARS-CoV-2 B.1.617.1 结构和结合行为的影响。
Int J Mol Sci. 2023 Jul 17;24(14):11564. doi: 10.3390/ijms241411564.
4
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.RBD-mRNA 疫苗诱导针对奥密克戎和多种其他变体的广泛中和抗体，并保护小鼠免受 SARS-CoV-2 挑战。
Transl Res. 2022 Oct;248:11-21. doi: 10.1016/j.trsl.2022.04.007. Epub 2022 Apr 28.
5
SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy.SARS-CoV-2 Delta 变体：个体突变及其变构协同作用的相互作用。
Biomolecules. 2022 Nov 23;12(12):1742. doi: 10.3390/biom12121742.
6
Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.SARS-CoV-2 变异株 Kappa、Delta 和 Lambda 对 Bamlanivimab 耐药性的结构-功能分析。
J Chem Inf Model. 2021 Oct 25;61(10):5133-5140. doi: 10.1021/acs.jcim.1c01058. Epub 2021 Oct 14.
7
Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.SARS-CoV-2 的变异体及其对感染、传播和疫苗诱导抗体中和作用的影响。
Eur Rev Med Pharmacol Sci. 2021 Sep;25(18):5857-5864. doi: 10.26355/eurrev_202109_26805.
8
Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy.意大利伦巴第地区流行的一种对中和抗体敏感性降低的谱系 C.36 SARS-CoV-2 分离株的特征。
Viruses. 2021 Jul 31;13(8):1514. doi: 10.3390/v13081514.
9
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.SARS-CoV-2 变体 B.1.617.1 (Kappa)、B.1.617.2 (Delta) 和 B.1.618 的细胞进入和免疫逃逸特性。
mBio. 2022 Apr 26;13(2):e0009922. doi: 10.1128/mbio.00099-22. Epub 2022 Mar 10.
10
Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.关注的紧急 SARS-CoV-2 变异株：用于快速检测和监测的新型多重实时 RT-PCR 检测方法。
Microbiol Spectr. 2022 Feb 23;10(1):e0251321. doi: 10.1128/spectrum.02513-21.

引用本文的文献

1
Differential Impact of Spike Protein Mutations on SARS-CoV-2 Infectivity and Immune Evasion: Insights from Delta and Kappa Variants.刺突蛋白突变对SARS-CoV-2传染性和免疫逃逸的差异影响：来自德尔塔和卡帕变体的见解
J Microbiol Biotechnol. 2024 Dec 28;34(12):2506-2515. doi: 10.4014/jmb.2411.11001. Epub 2024 Dec 2.
2
VIPERA: Viral Intra-Patient Evolution Reporting and Analysis.VIPERA：病毒患者内进化报告与分析
Virus Evol. 2024 Mar 6;10(1):veae018. doi: 10.1093/ve/veae018. eCollection 2024.
3
The emergence and successful elimination of SARS-CoV-2 dominant strains with increasing epidemic potential in Taiwan's 2021 outbreak.台湾地区2021年疫情中具有不断增加的流行潜力的新冠病毒优势毒株的出现与成功消除。
Heliyon. 2023 Nov 20;9(12):e22436. doi: 10.1016/j.heliyon.2023.e22436. eCollection 2023 Dec.
4
Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India.印度高度突变 BA 变异株的基因组特征、系统发育评估和时空动态研究。
Indian J Med Microbiol. 2023 May-Jun;43:66-72. doi: 10.1016/j.ijmmb.2022.10.006. Epub 2022 Nov 15.
5
Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination.老年人接种两剂 mRNA 疫苗后对 SARS-CoV-2 变异体的有效免疫应答。
Nat Commun. 2022 May 24;13(1):2891. doi: 10.1038/s41467-022-30617-9.
6
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants.抗体工程提高了对K417刺突突变型SARS-CoV-2变体的中和活性。
Cell Biosci. 2022 May 17;12(1):63. doi: 10.1186/s13578-022-00794-7.
7
Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification.评估一种快速、便捷的逆转录定量 PCR 方法，用于鉴定 SARS-CoV-2 关注变异株。
J Clin Microbiol. 2022 May 18;60(5):e0017822. doi: 10.1128/jcm.00178-22. Epub 2022 Apr 25.
8
SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India.印度第二波 COVID-19 大流行中涉及的 SARS-CoV-2 变体和刺突突变。
Transbound Emerg Dis. 2022 Sep;69(5):e1721-e1733. doi: 10.1111/tbed.14508. Epub 2022 Mar 24.
9
Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions.新型变体对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染性和中和作用的影响：刺突蛋白与宿主蛋白相互作用改变的分子评估
iScience. 2022 Mar 18;25(3):103939. doi: 10.1016/j.isci.2022.103939. Epub 2022 Feb 17.
10
Differences in Clinical Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected Patients.Delta变异株与野生型SARS-CoV-2感染患者的临床特征差异
Front Med (Lausanne). 2022 Jan 3;8:792135. doi: 10.3389/fmed.2021.792135. eCollection 2021.

本文引用的文献

1
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.针对多种高传染性 SARS-CoV-2 变体的超强效抗体。
Science. 2021 Aug 13;373(6556). doi: 10.1126/science.abh1766. Epub 2021 Jul 1.
2
Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance.用于人群水平变异筛选和流行病学监测的多重 SARS-CoV-2 基因分型逆转录 PCR。
J Clin Microbiol. 2021 Jul 19;59(8):e0085921. doi: 10.1128/JCM.00859-21.
3
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.全面绘制影响多克隆人血浆抗体识别的 SARS-CoV-2 受体结合域突变图谱。
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. doi: 10.1016/j.chom.2021.02.003. Epub 2021 Feb 8.
4
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响：一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
5
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
6
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.超强效人源抗体通过多种机制预防 SARS-CoV-2 感染。
Science. 2020 Nov 20;370(6519):950-957. doi: 10.1126/science.abe3354. Epub 2020 Sep 24.
7
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.SARS-CoV-2 刺突突变对病毒感染力和抗原性的影响。
Cell. 2020 Sep 3;182(5):1284-1294.e9. doi: 10.1016/j.cell.2020.07.012. Epub 2020 Jul 17.